Understanding the mechanism of action of a novel dual CAR approach with improved efficacy and safety using Cell Avidity Watch this webinar to learn how cell avidity was used to understand the mechanism of action of the trans-singalling stratergy of dual CAR-CIK cellsAdrià Ferragut5 June 2024
Improving CAR-T Immunotherapy for Lymphoma by fine-tuning avidity Commercial CAR-T therapies still suffer from severe limitations, as majority of patients fail to achieve complete response and ultimately relapse.Adrià Ferragut20 March 2024
Cell avidity of CAR-NK cells revealed as the best and earliest predictive parameter for 𝙞𝙣 𝙫𝙞𝙫𝙤 tumor control Dr. Peter Chockley demonstrates how cell avidity measurements directly linked to synapse quality and in vivo tumor clearance using CAR-NK avidity-tuned cellsAdrià Ferragut17 January 2024
How cell avidity between tumor-effector cell pairs drives the efficacy of cellular immunotherapy Measuring cell avidity provides a more complete and physiologically relevant picture of the cell-cell interaction.Adrià Ferragut22 September 2023
TCR- and BsAb-induced interaction drives avidity-based cellular immunotherapy efficacy Cell avidity measures the effectiveness of the events during immunological synapse formation.Adrià Ferragut22 September 2023
Unveiling a one-to-one relationship of TCR-dependent T cell function and cellular avidity at single-cell level using acoustic force The cell avidity experiments provided for the team of Dr. Nathalie Rufer shows a better in vivo correlation.Adrià Ferragut22 September 2023
Dual-targeted cell therapy targeting BCMA and GPRCD5 to prevent relapse in multiple myeloma Prof. de Larrea demonstrated reduced relapse through dual-targeting CAR T approaches.Adrià Ferragut22 September 2023
Exploring the network of cellular interactions of Natural Killer cells in the tumor microenvironment with cell avidity Prof. Mark Lowdell discussed how primed NK cells become effective in resistant tumor cell killing through stronger binding.Adrià Ferragut22 September 2023
Enhanced avidity through combining a BCMA CAR and a CD38 chimeric co-stimulatory receptor leads to enhanced T cell sensitivity and persistence Dr. Maria Themeli showed how to overcome low antigen density and improve CAR-T cell persistence with multi-targeting and co-stimulation.Adrià Ferragut22 September 2023
Cell avidity as a crucial biomarker for CAR T response Dr. Rebecca Larson's work revealed important evasion mechanism from CAR T cell response in solid tumors.Adrià Ferragut22 September 2023